Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
105.2 USD | -1.41% |
|
-1.11% | +14.06% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.06% | 6.59B | B- | ||
+35.14% | 51.51B | B- | ||
-7.43% | 39.03B | B | ||
+35.88% | 38.91B | A | ||
-10.62% | 26.68B | C | ||
+11.63% | 26.13B | B- | ||
-17.77% | 19.91B | B | ||
+40.52% | 13.71B | B+ | ||
+30.70% | 12.38B | C+ | ||
-3.41% | 11.74B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BPMC Stock
- Ratings Blueprint Medicines Corporation